✨ Medicines Notices
NEW ZEALAND GAZETTE
No. 73
executed on the 14th day of July 1997. A copy of the supplementary agreement is available for inspection without charge by any member of the public at the district office of the Ministry of Education, 39–45 College Hill, Ponsonby, Auckland.
Dated at Wellington this 14th day of July 1997.
ANNE DEVONSHIRE, for KATHY PHILLIPS, Senior Manager, National Operations.
g04911
Health
Medicines Act 1981
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act, and are set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Fluticasone propionate 125 mcg, 250 mcg per actuation | Spray, oral, metered dose | Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom and Laboratoire Glaxo Wellcome, Evreux, France | Flixotide |
| Paracetamol 24 mg/mL, 50 mg/mL in 2L | Suspension, oral | Douglas Pharmaceuticals Limited, Mount Wellington, Auckland | Paracetamol |
| Paracetamol 24 mg/mL, 50 mg/mL in 100 mL, 200 mL | Suspension, oral | Douglas Pharmaceuticals Limited, Mount Wellington, Auckland | Paracetamol (Pharmacycare) |
| Ramipril 1.25 mg, 2.5 mg, 5 mg, 10 mg | Tablets | Hoechst AG., Frankfurt (Main), Germany | Tritace |
| Didanosine 25 mg, 50 mg, 100 mg, 150 mg | Tablets, chewable/dispersible | Bristol-Myers Squibb Co, Evansville, Indiana, United States of America | Videx (mandarin orange flavour) |
Dated this 11th day of July 1997.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.
g04907
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Polio virus type I 40 D units, polio virus type II 8 D units, polio virus type III 32 D units in 0.5 mL | Vaccine, injection, pre-filled syringe | Pasteur Merieux Serums et Vaccins SA., Marcy L'Etoile, France | Ipol |
| Phenobarbitone sodium 20 mg in 0.5 mL | Injection, ampoule | David Bull Laboratories Limited, Mulgrave North, Victoria, Australia | Phenobarbitone |
| Selegiline hydrochloride 5 mg, 10 mg | Tablets | Alphapharm Pty Limited, Carole Park, Brisbane, Australia | Selgene |
| Penciclovir 1% w/w in 2 g, 5 g | Cream, tube | SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, Sussex, England | Vectavir |
| Penciclovir 1% w/w in 2 g | Cream, pump | SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, Sussex, England | Vectavir |
Dated this 12th day of July 1997.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.
g04908
Next Page →
NZ Gazette 1997, No 73
✨ LLM interpretation of page content
🏥 Consent to the Distribution of Changed Medicines
🏥 Health & Social Welfare11 July 1997
Medicines, Distribution, Consent, Fluticasone, Paracetamol, Ramipril, Didanosine
- G. R. Boyd, Chief Advisor, Regulation and Safety
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare12 July 1997
Medicines, Distribution, Consent, Polio virus, Phenobarbitone, Selegiline, Penciclovir
- G. R. Boyd, Chief Advisor, Regulation and Safety